PSNL Personalis Inc.

11.39
-0.37  -3%
Previous Close 11.76
Open 11.75
Price To Book 3.19
Market Cap 355,754,793
Shares 31,233,959
Volume 579,812
Short Ratio
Av. Daily Volume 471,986
Stock charts supplied by TradingView

NewsSee all news

  1. Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients.

  2. Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a

  3. Personalis, Inc. to Present at NeoAg Summit US 2019

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST. The presentation, entitled

  4. Personalis to Present at Upcoming Investor Conferences

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the

  5. Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

  1. Personalis, Inc. Announces the Launch of the NeXT Dx™ Test, a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients.

  2. Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a

  3. Personalis, Inc. to Present at NeoAg Summit US 2019

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the NeoAg Summit US 2019 in Boston on November 21st at 9:15 AM EST. The presentation, entitled

  4. Personalis to Present at Upcoming Investor Conferences

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the

  5. Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of

  6. Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place

  7. Personalis Reports Third Quarter 2019 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today reported financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Highlights Record revenues of $17.2

  8. Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced the launch of Personalis' Cancer Whole Genome Sequencing which further extends Personalis' portfolio of comprehensive cancer

  9. Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD,